Compared to Major Pharmaceutical and Biotech Companies
Top-Tier in Both Talent and R&D Investment

Samsung EPIS Holdings, which was established last year, has made a bold move by investing heavily in research and development (R&D), entering the competition for innovative new drug development in earnest. The company is focusing its entire organizational capabilities on securing outstanding research talent and expanding its infrastructure, aiming to move beyond its traditional biosimilar-focused business structure and become a global developer of innovative new drugs.


Samsung EPIS Holdings Makes Bold New Drug R&D Bet: Invests 247.4 Billion Won and Secures 620 Researchers View original image

According to an analysis of last year's business reports from 11 major domestic pharmaceutical and biotechnology companies on March 23, Samsung EPIS Holdings ranked among the industry's top tier in both R&D investment scale and the number of core research personnel. As of last year, Samsung EPIS Holdings' R&D expenditures totaled 247.4 billion won, which is approximately 47 billion won higher than the average R&D spending of the top 10 domestic pharmaceutical and biotech companies, which stands at 200.2 billion won. Although other leading domestic companies are also pouring more than 200 billion won on average annually into R&D and engaging in fierce investment competition, Samsung EPIS Holdings, a relatively new player in the new drug sector, has made even bolder investments. The ratio of R&D expenses to sales was 14.8%, surpassing the average of top companies, which was 12.1%. This figure reflects the company's intention to focus not on short-term profit improvement, but on creating innovative new drugs that can compete in the global market from a long-term perspective.


Samsung EPIS Holdings has also delivered remarkable results in securing outstanding research talent. As of the end of last year, the company employed 620 dedicated R&D personnel, a figure significantly exceeding the industry leader average of 433 research staff. Notably, the proportion of highly educated specialists, a key competitive factor in new drug development, is overwhelming. There are 158 PhD holders and 237 master's degree holders, totaling 395 researchers with advanced degrees—more than 63% of the total research workforce. In comparison, other top companies in the industry have deployed about 290 researchers with master's or doctoral degrees out of an average total of 395 research staff. In order to flexibly incorporate high-level technologies such as artificial intelligence (AI)-based drug development and next-generation modalities—topics that have recently come to the forefront of the global pharmaceutical industry—throughout the entire new drug development cycle, securing such specialized personnel is essential. By proactively recruiting a large number of highly skilled talent, Samsung EPIS Holdings aims to simultaneously improve the quality of its research and development, and maximize productivity, for example by discovering target substances for intractable diseases.



Following a spin-off from Samsung Biologics last year, Samsung EPIS Holdings was launched as a holding company serving as a platform for new drug development and investment. In addition to its existing biosimilar business, it is expanding into areas such as antibody-drug conjugates (ADC), peptides, and platform technologies. Samsung Bioepis, its subsidiary, plans to actively expand its new drug development business, starting with the launch of the global Phase 1 clinical trial for its first new drug candidate (SBE303) this year and aiming to enter at least one Investigational New Drug (IND) stage annually. Recently, its subsidiaries Samsung Bioepis and Epis Nexlab signed a joint research and license agreement with G2GBio for the development of a long-acting obesity treatment. An industry insider commented, "Samsung EPIS Holdings' large-scale investment is not only expanding its own pipeline, but is also encouraging healthy competition among major pharmaceutical and biotechnology companies, serving as a positive catalyst for expanding the overall K-bio ecosystem." Reported by Jung Donghoon and Lee Sungmin.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing